REGEN BIOPHARMA, INC. Pre-Tax Income
REGEN BIOPHARMA, INC. (RGBP) reported Pre-Tax Income of -$637.78 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Income Statement
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest · last filed 2026-08-17
- REGEN BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-06-30 was -$637.78K.
- REGEN BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2026-03-31 was $991.93K.
- REGEN BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-12-31 was -$967.85K.
- REGEN BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for the quarter ending 2025-09-30 was -$572.47K.
- REGEN BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2025 was -$1.27M.
- REGEN BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2024 was -$668.25K, a 157.78% decline from fiscal 2023.
- REGEN BIOPHARMA, INC. income (loss) from continuing operations before income taxes, noncontrolling interest for fiscal 2023 was $1.16M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$637.78K 10-Q · filed 2026-08-17 | $354.14K derived: sum of 2 quarters · filed 2026-08-17 | -$613.71K 10-Q · filed 2026-08-17 | -$1.19M derived: sum of 4 quarters · filed 2026-08-17 |
| 2026-03-31 | $991.93K 10-Q · filed 2026-05-14 | $24.07K 10-Q · filed 2026-05-14 | -$548.39K derived: sum of 3 quarters · filed 2026-05-14 | -$715.69K derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-12-31 | -$967.85K 10-Q · filed 2026-02-13 | -$1.54M derived: sum of 2 quarters · filed 2026-02-13 | -$1.71M derived: sum of 3 quarters · filed 2026-08-17 | -$1.73M derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-09-30 | -$572.47K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-30 | -$739.76K derived: sum of 2 quarters · filed 2026-08-17 | -$759.12K derived: sum of 3 quarters · filed 2026-08-17 | -$1.27M 10-K · filed 2025-12-30 |
| 2025-06-30 | -$167.29K 10-Q · filed 2026-08-17 | -$186.65K derived: sum of 2 quarters · filed 2026-08-17 | -$702.03K 10-Q · filed 2026-08-17 | -$972.78K derived: sum of 4 quarters · filed 2026-08-17 |
| 2025-03-31 | -$19.35K 10-Q · filed 2026-05-14 | -$534.74K 10-Q · filed 2026-05-14 | -$805.49K derived: sum of 3 quarters · filed 2026-05-14 | -$935.61K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$515.38K 10-Q · filed 2026-02-13 | -$786.13K derived: sum of 2 quarters · filed 2026-02-13 | -$916.25K derived: sum of 3 quarters · filed 2026-02-13 | -$1.04M derived: sum of 4 quarters · filed 2026-02-13 |
| 2024-09-30 | -$270.75K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-30 | -$400.87K derived: sum of 2 quarters · filed 2025-12-30 | -$523.32K derived: sum of 3 quarters · filed 2025-12-30 | -$668.25K 10-K · filed 2025-12-30 |
| 2024-06-30 | -$130.12K 10-Q · filed 2025-08-11 | -$252.57K derived: sum of 2 quarters · filed 2025-08-11 | -$397.51K 10-Q · filed 2025-08-11 | |
| 2024-03-31 | -$122.45K 10-Q · filed 2025-05-28 | -$267.39K 10-Q · filed 2025-05-28 | ||
| 2023-12-31 | -$144.93K 10-Q · filed 2025-05-16 | |||
| 2023-09-30 | $1.16M 10-K · filed 2025-05-13 |